SOS1 inhibitor in Evopoint will be displayed in the 7th JCA-AACR
About XNW22013
XNW22013 is a small molecule SOS1 inhibitor with
independent intellectual property rights owned by Evopoint. It can be used
jointly with XNW14011, another KRASG12C inhibitor independently developed by
Evopoint, to treat tumors with KRASG12C mutation.
According to preclinical trial data, XNW22013 outperforms
products of the same category in terms of in vitro and in vivo efficacy, safety, absorption, distribution, metabolism and excretion (ADME),
pharmacokinetics (PK), etc. It is expected to become a best-in-class SOS1
inhibitor against pan-KRAS mutations all over the world.
About SOS1
SOS1 is a guanylate exchange factor (GEF),
which can activate the process of RAS-GDP transforming into RAS-GTP. Selective
inhibitors of SOS1 can bind to the catalytic domain of SOS1 to prevent the
interaction with KRAS and simultaneously block SOS1-driven feedback. Meanwhile,
selective inhibitors of SOS1 can block KRAS without being affected by the types
of KRAS mutations, thus inhibiting KRAS-dependent tumors. As high as 90% of
patients with pancreatic cancer have KRAS mutations. Recently, more attention
is being paid to and more progress is being made on medicinal regulation of
SOS1, a target in the upstream of KRAS mutation, which may facilitate the
development of optimized combined therapeutic schedules for KRAS mutations.
